💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sacubitril-Valsartan

Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
11.5 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
414.5 g/mol
LogP
—
Phase
4

Sacubitril-valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) combining sacubitril (a neprilysin inhibitor prodrug) and valsartan (an angiotensin II receptor blocker) for heart failure treatment. Sacubitril inhibits neprilysin-mediated breakdown of natriuretic peptides, bradykinin, and other vasoactive substances, while valsartan blocks AT1 receptors, producing complementary vasodilatory and cardioprotective effects. It has demonstrated superior outcomes to ACE inhibitors in patients with heart failure with reduced ejection fraction.

น้ำหนักโมเลกุล

414.5010 g/mol

TPSA

205.00 Ų

ด้านการรักษา

Thyroid Cancer Cardiovascular Disease Systemic Lupus Erythematosus Chronic Kidney Disease Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer HIV/AIDS Heart Failure Atrial Fibrillation

หมวดหมู่ยา

C — C - Cardiovascular System

กลไกการออกฤทธิ์

Angiotensin receptor-neprilysin inhibitor (ARNI) combining neprilysin inhibition with AT1 receptor blockade.

Pharmacokinetics (PK)

Half-Life 11.5 hours

Pharmacodynamics (PD)

กลไก

Angiotensin receptor-neprilysin inhibitor (ARNI) combining neprilysin inhibition with AT1 receptor blockade.

SMILES

CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O.CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O

InChI

InChI=1S/C24H29N5O3.C24H29NO5/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28);4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)/t22-;17-,21+/m01/s1

Molecular Formula

C24H29N2O5

HBD / HBA

4 / 11

พันธะที่หมุนได้

22

อะตอมหนัก

62

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Sacubitril-valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) combining sacubitril (a neprilysin inhibitor prodrug) and valsartan (an angiotensin II receptor blocker) for heart failure treatment. Sacubitril inhibits neprilysin-mediated breakdown of natriuretic peptides, bradykinin, and other vasoactive substances, while valsartan blocks AT1 receptors, producing complementary vasodilatory and cardioprotective effects. It has demonstrated superior outcomes to ACE inhibitors in patients with heart failure with reduced ejection fraction.

Angiotensin receptor-neprilysin inhibitor (ARNI) combining neprilysin inhibition with AT1 receptor blockade.

Key pharmacokinetic parameters for Sacubitril-Valsartan: Half-life: 11.5 hours.

Yes, Sacubitril-Valsartan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

ADME Journey →

Related Drugs

Same Drug Class

Atorvastatin Small molecule Amlodipine Small molecule Lisinopril Small molecule Metoprolol Small molecule
{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • PubChem — National Center for Biotechnology Information (NCBI). CID 24755620. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.